News

Public · Published

JP Morgan maintains Amneal Pharmaceuticals at Overweight, raises price target to $25 from $24

JP Morgan maintained its Overweight rating on Amneal Pharmaceuticals and raised its price target to $25 from $24. The new target is 4.2% higher than the previous one and implies 23.7% upside from the November 3 closing price of $20.21.

Published:

Updated:

What happened

JP Morgan maintained its Overweight rating on Amneal Pharmaceuticals and raised its price target to $25 from $24. The new target is 4.2% higher than the previous one and implies 23.7% upside from the November 3 closing price of $20.21.

Confirmed

Global impact / market context

A higher target signals that JP Morgan sees more potential value in Amneal shares than before, while keeping its positive rating unchanged. If investors act on that view, increased buying could support the share price, but the target is an analyst estimate, not a guaranteed outcome.

Analyst inference

The article provides one analyst’s updated view, not company results or a change in Amneal’s business outlook. Its stated 23.7% upside compares the new target with the November 3 close, so it does not establish how the shares have moved since then.

Analyst inference

What to watch

  1. Watch for Amneal’s later share price relative to the $25 target; the article gives no subsequent price or evidence that the implied upside has been reached. Analyst inference
  2. Look for future JP Morgan rating or target changes, which could show whether the analyst continues to hold a positive view or revises it. Analyst inference
  3. Company updates on sales, costs, or cash available could help investors judge whether business performance supports the higher analyst target; none are included here. Analyst inference

Evidence

  • Original source link unavailable